ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — Canaccord Genuity Presentation (August 2011)

25 slides from ReShape Lifesciences's conference presentation, Aug 11, 2011

  1. Slide 1: Canaccord Genuity Presentation

    Exhibit 99.1 Canaccord Genuity Presentation August 11, 2011

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Thispresentationcontainsforward-lookingstatementsabout EnteroMedicsInc. Our actual results could differ materiallyfrom those discusseddue to known and unknown risks,uncertaintiesand other factors includingour limited history of operations;our lossessinceinceptionand for the for

  3. Slide 3: EnteroMedics: Leader in neuroblocking with strong IP

    EnteroMedics Leader in neuroblocking with strong IP Data in >400 patients support VBLOC therapy as safe and effective in obesity. Promising results in type 2 diabetes – Clinically significant weight loss – Improvement in glycemic control – Reduction in blood pressure in hypertensive patients – Excel

  4. Slide 4: The Obesity Epidemic in the US

    The Obesity Epidemic in the US 1/3 of US adults are obese – More than 72 million people in the US (Body Mass Index “BMI” >30) – 1 in 8 deaths in the US are caused by an overweight/obesity related illness – CDC estimates an overall economic cost of obesity of approximately $150 billion Approximately

  5. Slide 5: Current Treatments

    Current Treatments Pharmaceuticals Bariatric Surgery Less Invasive More Invasive Serious safety concerns, esp. cardiac Bypass & sleeve surgery irreversible and risky Adverse side-effects All result in long-term complications and major lifestyle changes, e.g., dietary restrictions and nutritional Les

  6. Slide 6: Role of the Vagus Nerve

    Role of the Vagus Nerve Vagus nerve controls: – Sensation of hunger 20% of vagus – Expansion, fullness and emptying nerve fibers send of stomach instructions from the brain – Digestive enzyme secretion Severing the vagus nerve (vagotomy) causes: 80% of vagus nerve fibers – Reduced appetite send mess

  7. Slide 7: VBLOC Therapy

    VBLOC Therapy Delivered via the Maestro System VBLOC Therapy – First in class n –on-punitive; direct effect on mechanism of metabolic disease – Intermittent neuroblockingtechnology blocks vagus nerve signals, therefore reducing hunger feelings and promoting earlier fullness – Subcutaneously implante

  8. Slide 8: Compelling Proof of Concept

    Compelling Proof of Concept Significant impact on hunger and fullness drives successful weight loss Earlier Fullness and Less Hunger Reduced Portion Size Reduced Calories 90% 2250 30% Earlier Protein Carbohydrates Fat % EWL from 25% fullness 2000 Implant 20% 60% 1750 20% 15% 10% 30% 1500 5% 0% 1250

  9. Slide 9: The Maestro System

    The Maestro System Clinical Experience Safety Efficacy No therapy related SAEs; Low overall SAE rate Clinically significant weight-loss Positive safety profile, including CV Control of major co-morbidities – Diabetes and hypertension Study Location # Patients Study Efficacy ~400 Overall Duration (yr

  10. Slide 10: Pivotal Trials

    Pivotal Trials EMPOWER – 294 subjects Double blind, placebo controlled randomized trial BMI range 35 to 39.9 with co-morbidity; 40 to 45 with or without – Endpoints Primary efficacy: Greater efficacy in treated arm versus control arm Secondary efficacy: Greater proportion of treated subjects versus

  11. Slide 11: Maestro System: Usage equals Results

    Maestro System Usage equals RESULTS EMPOWER Trial Outcome Mean Excess Weight Loss (EWL) by Hours of Use in Treatment Group 0 “Dose Effect”shows clear < 6hr correlation between -5 (n = 25) average EWL and the -10 number of hours of device 6 - 9hr (n = 61) use -15 – Demonstrates efficacy -20 9 - 12hr

  12. Slide 12: EMPOWER Trial Summary

    EMPOWER Trial Summary Both groups experienced significant, dose-dependent Excess Weight Loss (EWL) – EWL greater than 20% in the prescribed use group of both arms – An unanticipated therapeutic effect was seen in the placebo arm Safety endpoint met – No deaths, low 1-yr surgical revision rate and lo

  13. Slide 13: US RECHARGE Trial

    US RECHARGE Trial Pivotal Trial for US Approval Use next generation implantable device – More convenient – Hours of use controlled by device Placebo group receives non-active device – No charge delivered Approximately 234 morbidly obese subjects – 2:1 randomization – Treated group “on”for ~12 hrs pe

  14. Slide 14: VBLOC-DM2 ENABLE Trial

    VBLOC –DM2 ENABLE Trial Diabetes and Hypertension Design:prospective, open-label, multi-center, 12 month trial Cohort:28 patients with obesity and type 2 diabetes, 18 with hypertension Inclusion criteria: – BMI 30 to 40 kg/m2 – NIDDM, <12 yrs duration – HbA1c levels >7% to <10% – Absence of signific

  15. Slide 15: VBLOC-DM2 ENABLE Trial: %EWL Results

    VBLOC –DM2 ENABLE Trial %EWL Results 0 -5 -10 - 15 - 20 - 25 n=26 -30 n=24 n=22 n=24 - 35 Implant 3 Months 6 Months 12 Months 18 Months *N represents subjects using the device for 12 hours or more 15

  16. Slide 16: Change in Fasting Glucose

    Change in Fasting Glucose Week 1 Week 4 Week 12 6 Months 12 Months 18 Months 0 -10 -20 * * -30 n=28 n=27 * n=26 * -40 n=25 * n=25 -50 At all time points, changes are significant with p<0.01 * Baseline= 151.4± 6.5 mg/dl n=12 -60

  17. Slide 17: Change in HbA1c %

    Change in HbA1c % Week 1 Week 4 Week 12 6 Months 12 Months 18 Months 17

  18. Slide 18: Change in Diastolic Blood Pressure in Patients with Elevated DBP

    Change in Diastolic Blood Pressure in Patients with Elevated DBP Week 1 Wk 1 Week 4 Wk 4 6 Months 6 Mo 12 12 Months Mo 1818Months Mo 0 -5 n= 12 n= 12 n= 11 -10 n= 10 -15 n= 10 -20 At all time points statistically significant with p<.01 Baseline= 87.5± 2.2 mmHg

  19. Slide 19: Change in Mean Arterial Pressure in Patients with Hypertension

    Change in Mean Arterial Pressure in Patients with Hypertension Week 1 Week 12 6 Months 12 Months 18 Months 0 -5 n= 15 n= 14 n= 14 -10 n= 13 n= 13 -15 At all time points statistically significant with p=.04 Baseline= 100.1± 2.4mmHg -20

  20. Slide 20: No Change in Blood Pressure in Normotensive Patients

    No Change in Blood Pressure in Normotensive Patients Week 1 Week 4 Week 12 6 Months 12 Months 10 3.2 8 n=4 6 0.5 4 n=10 2 0 -2 -4 -1.0 -1.8 -6 n=10 n=10 -8 -3.2 Baseline MAP = 89.0 ±1.1 mmHg n=10 -10 Week 1 Week 4 Week 12 6 Months 12 Months

  21. Slide 21: Significant Promise in Treatment of Metabolic Disease

    Significant Promise in Treatment of Metabolic Disease Diabetes and Hypertension Clinically significant effect of VBLOC on two major co-morbidities – Type 2 Diabetes Mellitus • About 26 million people in US and more than 220 million people worldwide have diabetes – Cardiovascular / blood pressure • A

  22. Slide 22: Commercialization in Europe and Australia

    Commercialization in Europe and Australia Australia – Historical leadership with new obesity treatments – Extensive clinical experience with the Maestro System • Australian Institute of Weight Control (AIWC) – Device Technologies Australia • Distributor • Regulatory and reimbursement support – TGA a

  23. Slide 23: Financial Summary

    Financial Summary Balance Sheet Data NASDAQ: ETRM As of June 30, 2011 Diluted Shares Outstanding Cash and cash equivalents $27.4 million As of June 30, 2011 Total invested capital CommonShares $171 million 27.9 million Warrants 22.2 million Options 2.0 million DilutedSharesOutstanding 52.1million 23

  24. Slide 24: EnteroMedics: Leader in neuroblocking with strong IP

    EnteroMedics Leader in neuroblocking with strong IP Data in >400 patients support VBLOC therapy as safe and effective in obesity. Promising results in type 2 diabetes – Clinically significant weight loss – Improvement in glycemic control – Reduction in blood pressure in hypertensive patients – Excel

  25. Slide 25: Slide 25

EnteroMedics — Canaccord Genuity Presentation (August 2011) on 6ix